The FDA's Cell, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 9 to 3 against recommending approval for Capricor Therapeutics' deramiocel (developmental name: 'CAP-1002') for the treatment of Duchenne muscular dystrophy (DMD)-related cardiomyopathy on July 29, 2026. Committee members raised significant concerns regarding the timing of the Statistical Analysis Plan (SAP) changes and the reliability of missing data handling in the Phase 3 (HOPE-3) trial. They determined that post-hoc modifications to the statistical model could have introduced bias into the results. This decision highlights the critical role of statistical transparency in the development of rare disease therapies and its impact on regulatory approval.

Deramiocel's mechanism of action involves exosomes secreted from allogeneic cardiac progenitor cells (CDC), which modulate the immune system and inhibit myocardial fibrosis. The Phase 3 trial results were published in 'The Lancet,' demonstrating a 54% delay in functional decline (p=0.029) at 12 months compared to placebo, as assessed by the upper limb function test (PUL 2.0). However, key secondary endpoints related to cardiac function, such as left ventricular ejection fraction (LVEF), lost statistical significance in the post-hoc analysis (p=0.09). Consequently, the advisory committee concluded that the drug failed to demonstrate a direct improvement in cardiac function, leading to concerns about the strength of the efficacy evidence.

Capricor had established significant global partnerships, including a commercialization agreement with Nippon Shinyaku for the U.S. market (upfront payment of $30 million, potential milestone payments of up to $750 million) and a European commercialization agreement (upfront payment of $20 million, potential milestone payments of up to $715 million). However, in May 2026, Capricor initiated a lawsuit against Nippon Shinyaku's U.S. subsidiary, NS Pharma, citing deficiencies in the pricing structure as grounds for terminating the U.S. commercialization agreement. Combined with the advisory committee's negative recommendation, the prospects for receiving substantial milestone payments have become uncertain, and the associated litigation costs have increased. This poses a significant financial risk for the cash-strapped biotech company, and investors should exercise caution.

The global DMD therapeutics market is estimated at $3.1 billion to $5.31 billion in 2025-2026, with Sarepta's gene therapy, Elevidys, leading the competitive landscape. However, Elevidys's 2025 sales were limited to $898.7 million due to safety concerns and restrictions on prescribing to ambulatory patients, and Sarepta's overall DMD revenue forecast for 2026 has been revised down to $1.2 billion to $1.4 billion. Deramiocel aimed to address the major cause of death in DMD patients, namely cardiomyopathy, and capture this market segment. The advisory committee's negative recommendation now threatens to delay market entry and jeopardize the opportunity to establish a dominant competitive advantage.

The FDA's final decision, which will be made by the PDUFA target action date of August 22, 2026, represents a significant near-term investment risk. While the advisory committee's vote is non-binding, the FDA is highly likely to either reject the application or issue a Complete Response Letter (CRL) based on the committee's recommendations. Capricor's ability to secure approval by focusing on the positive data from the upper limb function (PUL 2.0) and narrowing the indication to upper limb function improvement, rather than cardiomyopathy, will be critical. Investors should prepare for potentially significant stock price volatility following the August announcement and adopt a conservative approach until the reliability of the clinical data is restored and the ongoing legal disputes are resolved.